Lumida
/PGEN
⌘K
Precigen Inc

Precigen Inc

PGEN
$6.85USD↑+2.54%+0.17 today

MARKET CAP

2.5B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$3
$8

AI Summary

Stalk
StalkMedium

PGEN remains in a Stage 2 advancing structure above the 50-day SMA, but the active Bullish Exhaustion pattern at late-August highs signals waning upside momentum. Price is pulling back into declining 9- and 20-day EMAs with RSI in a neutral range, offering a buy-on-dip setup. Medium-term bias stays bullish, while short-term timing is neutral—entries are best deferred until clear acceptance off the EMA zone.

  • ↑Q2 revenue $55M; Papimius sales $53.1M, up 145% QoQ
  • ↑FDA approval and 7-year orphan drug exclusivity for RRP therapy
  • ↓Insiders sold ~235K shares (~$1.38M), flagging possible concern
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Precigen, Inc. (NASDAQ:PGEN) is an emerging biotechnology company focused on innovative gene therapies, particularly for rare diseases. The company utilizes its proprietary adenoviral vector platform to develop treatments for conditions like recurrent respiratory papillomatosis (RRP). Its lead product, Papimius, is gaining attention for its promising results and FDA approval status, positioning Precigen within the significant growth trajectory of advanced therapeutics aimed at unmet medical needs.

Bull says

  • ↑Q2 revenue $55M; Papimius sales $53.1M, up 145% QoQ
  • ↑FDA approval and 7-year orphan drug exclusivity for RRP therapy
  • ↑H.C. Wainwright raised price target from $14 to $18 on buy rating
  • ↑$38.7M cash plus $71.9M receivables underpins funding runway
  • ↑Over 500 patients treated, tapping a significant unmet market need
  • ↑Strong momentum and growth factor signals support optimistic outlook

Bear says

  • ↓Insiders sold ~235K shares (~$1.38M), flagging possible concern
  • ↓Negative profitability metrics despite strong top-line growth
  • ↓Volatility remains elevated, heightening investor risk exposure
  • ↓Heavy reliance on Papimius sales raises single-product risk
  • ↓Valuation upside may largely be priced in after recent gains
  • ↓Competition and small size may hinder long-term market share

Investment themes with PGEN

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q2 2023 · Mgmt. Guidance

Updated 11-15-2025bullish

Transcript signals

Bull points

  • the ongoing single-arm phase 1-2 study will serve as the pivotal study to support BLA submission for an accelerated approval.
  • The ability of the ongoing Phase I-II to serve as a pivotal for accelerated approval can significantly reduce the developmental time to licensure.
  • today, we are pleased to report that all complete responders from the phase one, they remain surgery-free with a minimum follow-up of 18 months, and the responses are still ongoing.

Bear points

  • we had refrain from entering to the phase three because of the prioritization of the program and the cash requirement that the program had.
  • Precision does not have the cash requirements to go to extended phase 3s with this asset, and this is why we have the very active discussions with a number of parties around AG019.
Read full transcript analysis ›